• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.

作者信息

Bono P, Elfving H, Utriainen T, Osterlund P, Saarto T, Alanko T, Joensuu H

出版信息

Ann Oncol. 2009 Feb;20(2):393-4. doi: 10.1093/annonc/mdn729.

DOI:10.1093/annonc/mdn729
PMID:19211503
Abstract
摘要

相似文献

1
Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.贝伐单抗治疗晚期肾细胞癌的高血压及临床获益
Ann Oncol. 2009 Feb;20(2):393-4. doi: 10.1093/annonc/mdn729.
2
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.动脉高血压以及舒尼替尼、索拉非尼和贝伐单抗在转移性肾细胞癌一线及二线治疗中的临床获益
Ann Oncol. 2009 May;20(5):966-7; author reply 967. doi: 10.1093/annonc/mdp201.
3
Targeted Therapies: Bevacizumab and interferon-alpha in metastatic renal-cell carcinoma.靶向治疗：贝伐单抗与α干扰素治疗转移性肾细胞癌
Nat Rev Clin Oncol. 2009 May;6(5):253-4. doi: 10.1038/nrclinonc.2009.45.
4
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.舒尼替尼在贝伐单抗难治性转移性肾细胞癌患者中的抗肿瘤活性及生物标志物分析
J Clin Oncol. 2008 Aug 1;26(22):3743-8. doi: 10.1200/JCO.2007.15.5416.
5
New challenges in kidney cancer therapy: bevacizumab.
Ann Oncol. 2007 Jul;18 Suppl 9:ix89. doi: 10.1093/annonc/mdm300.
6
Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma.一名接受抗血管内皮生长因子（VEGF）治疗的转移性肾细胞癌患者出现蛋白尿。
Nat Clin Pract Nephrol. 2007 May;3(5):287-93. doi: 10.1038/ncpneph0476.
7
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.贝伐单抗联合干扰素α-2a治疗转移性肾细胞癌：一项随机、双盲III期试验。
Lancet. 2007 Dec 22;370(9605):2103-11. doi: 10.1016/S0140-6736(07)61904-7.
8
Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.贝伐珠单抗联合依维莫司治疗晚期肾细胞癌的 II 期临床试验。
J Clin Oncol. 2010 May 1;28(13):2131-6. doi: 10.1200/JCO.2009.26.3152. Epub 2010 Apr 5.
9
Bevacizumab as first-line therapy for patients with brain metastases from renal carcinoma: a case series.贝伐单抗作为肾癌脑转移患者的一线治疗：病例系列
Clin Genitourin Cancer. 2014 Jun;12(3):e107-10. doi: 10.1016/j.clgc.2013.12.005. Epub 2014 Jan 2.
10
Bevacizumab for renal cell carcinoma, glioblastoma, and other solid tumors.贝伐单抗用于治疗肾细胞癌、胶质母细胞瘤及其他实体瘤。
Oncology (Williston Park). 2009 Oct;23(11 Suppl Nurse Ed):54-6.

引用本文的文献

1
Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer.严重高血压的发生显著改善转移性结直肠癌regorafenib 治疗的无进展生存期。
Int J Clin Oncol. 2023 Sep;28(9):1183-1190. doi: 10.1007/s10147-023-02364-4. Epub 2023 Jun 15.
2
Current status and future perspectives of onco-cardiology: Importance of early detection and intervention for cardiotoxicity, and cardiovascular complication of novel cancer treatment.肿瘤心脏病学的现状与未来展望：早期发现和干预心脏毒性以及新型癌症治疗心血管并发症的重要性。
Glob Health Med. 2021 Aug 31;3(4):214-225. doi: 10.35772/ghm.2021.01024.
3
Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.
三线安罗替尼治疗期间发生高血压与鳞状细胞肺癌（SCC）患者的无进展生存期相关：ALTER0303 试验的事后分析。
Thorac Cancer. 2021 Sep;12(17):2345-2351. doi: 10.1111/1759-7714.14076. Epub 2021 Jul 17.
4
The prognostic significance of preexisting diabetes in patients with surgically treated renal cell carcinoma: the ongoing debate.手术治疗的肾细胞癌患者中既往糖尿病的预后意义：持续的争论。
Ann Transl Med. 2019 Dec;7(Suppl 8):S321. doi: 10.21037/atm.2019.09.131.
5
Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer.转移性透明细胞肾细胞癌抗血管生成治疗的预后及疗效生物标志物
Front Oncol. 2019 Dec 11;9:1400. doi: 10.3389/fonc.2019.01400. eCollection 2019.
6
[Austrian Consensus on High Blood Pressure 2019].《2019年奥地利高血压共识》
Wien Klin Wochenschr. 2019 Nov;131(Suppl 6):489-590. doi: 10.1007/s00508-019-01565-0.
7
Hypertension in malignancy-an underappreciated problem.恶性肿瘤中的高血压——一个未得到充分重视的问题。
Oncotarget. 2018 Apr 17;9(29):20855-20871. doi: 10.18632/oncotarget.25024.
8
Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial.毛细血管密度作为贝伐单抗治疗转移性结直肠癌疗效的早期生物标志物无价值：一项前瞻性临床试验
Oncotarget. 2017 Dec 1;9(16):12599-12608. doi: 10.18632/oncotarget.22822. eCollection 2018 Feb 27.
9
Low preoperative serum cholesterol level is associated with aggressive pathologic features and poor cancer-specific survival in patients with surgically treated renal cell carcinoma.术前血清胆固醇水平低与接受手术治疗的肾细胞癌患者侵袭性病理特征和癌症特异性生存不良相关。
Int J Clin Oncol. 2018 Feb;23(1):142-150. doi: 10.1007/s10147-017-1172-4. Epub 2017 Aug 8.
10
Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition: Effects on Renal Function.高血压与血管内皮生长因子（VEGF）受体酪氨酸激酶抑制：对肾功能的影响。
Hypertension. 2017 Jul 24. doi: 10.1161/HYPERTENSIONAHA.117.09275.